Scpharmaceuticals Inc (NASDAQ:SCPH) – Equities research analysts at Leerink Swann raised their FY2022 earnings per share estimates for shares of Scpharmaceuticals in a research note issued to investors on Thursday. Leerink Swann analyst A. Fadia now expects that the company will post earnings per share of $2.70 for the year, up from their prior estimate of $2.64. Leerink Swann has a “Outperform” rating and a $20.00 price objective on the stock.
A number of other equities research analysts have also issued reports on the stock. BMO Capital Markets started coverage on shares of Scpharmaceuticals in a report on Tuesday, December 12th. They set an “outperform” rating and a $24.00 target price for the company. Jefferies Group started coverage on shares of Scpharmaceuticals in a report on Tuesday, December 12th. They set a “buy” rating and a $23.00 target price for the company. Finally, Zacks Investment Research lowered shares of Scpharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th.
Scpharmaceuticals (NASDAQ:SCPH) last released its earnings results on Tuesday, March 20th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.27).
Several hedge funds have recently made changes to their positions in SCPH. Monashee Investment Management LLC acquired a new position in shares of Scpharmaceuticals during the 4th quarter valued at about $230,000. Bank of New York Mellon Corp acquired a new position in Scpharmaceuticals in the fourth quarter valued at about $414,000. Millennium Management LLC acquired a new position in Scpharmaceuticals in the fourth quarter valued at about $462,000. Goldman Sachs Group Inc. acquired a new position in Scpharmaceuticals in the fourth quarter valued at about $653,000. Finally, Bain Capital Public Equity Management LLC acquired a new position in Scpharmaceuticals in the fourth quarter valued at about $1,291,000. 44.22% of the stock is currently owned by hedge funds and other institutional investors.
scPharmaceuticals, Inc, is a biopharmaceutical company. The Company is engaged in developing pharmaceutical products for subcutaneous delivery. The Company offers sc2Wear Infusor, which is a small pump that attaches to the body using a standard medical adhesive. The sc2Wear Infusor injects the drug into the body slowly, similar to an intravenous (IV) drip.
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.